Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications

Author(s): Arieh Gertler, Eran Elinav

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 4 , 2014

Become EABM
Become Reviewer
Call for Editor


Random mutagenesis of mouse leptin antagonist (L39A/D40A/F41) followed by selection of high-affinity mutants by yeastsurface display indicated that replacing residue D23 with a non-negatively charged amino acid (most specifically with Leu) leads to dramatically enhanced affinity of leptin toward LEPR leading to development of superactive mouse, human, ovine and rat leptin antagonists (D23L/L39A/D40A/F41A). Superactive leptin antagonist mutants of mouse, human, rat or ovine leptins were developed in our laboratory, expressed in E. coli, refolded and purified to homogeneity as monomeric proteins. Pegylation of leptin antagonists resulted in potent and effective long-acting reagents suitable for in vivo studies or therapies. In the present review we explain the mechanism of leptin inhibition and summarize the possible use of leptin antagonists as possible leptin blockers in various human pathologies such as antiinflammatory and anti-autoimmune diseases, uremic cachexia, and cancer. We also suggest the use of leptin antagonists as research reagents for creation of a novel, fast and reversible model of T2DM in mice.

Keywords: Leptin, antagonist, inflammatory disease, anti-autoimmune diseases, cancer, uremic cachexia, T2DM model.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [659 - 665]
Pages: 7
DOI: 10.2174/13816128113199990014
Price: $65

Article Metrics

PDF: 37